Abstract:Abstract Background IgA Nephropathy (IgA N) is one of the most common glomerulopathies and may lead to renal failure in 10–20% of cases. After renal transplantation, IgA N has a strong tendency to recur in the graft. Initially considered a benign condition, graft losses from recurrent IgA N have been reported over the last 20 yr, casting doubt on the initial premise. Since large single‐center studies of the fate of renal allografts in IgA N are rare and the Mayo Clinic transplant experience for IgA N is extensive (dating back to 1970), a review of these issues appeared worthwhile. Methods A retrospective study was done of all renal transplant patients who had had biopsy‐proven IgA N as underlying disorder. We extracted data on the underlying disease, history leading to renal transplantation, factors affecting transplant outcome, and on the course after transplantation with special attention to rejection activity and recurrence of the primary disease. Standard statistical methods were employed. Results 53 renal allografts were transplanted to 51 biopsy‐proven IgA N patients: 12 were cadaveric (CAD) grafts, 3 HLA‐mismatched living related donor (LRD) kidneys, 29 one haplotype‐matched LRD and 9 HLA‐identical LRD organs. Five‐year actuarial graft survival was 100% in HLA‐ identical LRD, 88% in one haplotype‐matched LRD, and 74% in CAD grafts. All three HLA‐mismatched LRD kidneys were functioning up to 1.6 yr (longest follow‐up). Only one patient died after acute rejection of the CAD graft. There were 3 early graft losses from acute rejection and 4 late losses. IgA N recurred in 26% of allografts and led to significant loss of graft function in 10 of the 14 patients (71%) over a long period of observation. Three of four late graft losses were in patients with recurrent IgA N. Recurrence was not related to the type of graft, i.e. CAD vs. LRD, nor to the extent of HLA‐matching in LRD transplantation. Conclusion Renal transplantation in patients with IgA N has excellent patient and graft survival. There is a high rate of recurrence of the primary glomerulopathy in the renal allograft, and this event is by no means inconsequential. Loss of renal function and even graft loss occur over prolonged periods of time. There is no disadvantage getting a well matched LRD in regard to incidence of recurrent IgA N. Thus, we encourage LRD transplantation in IgA N.

IgA nephropathy.

Progress in Pathogenesis of Immunoglobin A Nephropathy

Clinical and Pathology Features of IgA Nephropathy with Active Tubular Interstitial Lesions

IgA nephropathy in a child with X-linked agammaglobulinemia: a case report

The pathophysiology of IgA nephropathy

Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases

Progress in molecular and genetic studies of IgA nephropathy

Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children

Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment

Characteristics of children with IgA nephropathy

Genome-wide association study identifies susceptibility loci for IgA nephropathy

IPNA Clinical Practice Recommendations for the Diagnosis and Management of Children with IgA Nephropathy and IgA Vasculitis Nephritis

Red blood cell casts induced acute renal failure in IgA nephropathy: a childhood case report with literature review

Renal histological changes in relation to renal function and urinary protein excretion in IgA nephropathy.

The fate of renal transplants in patients with IgA nephropathy

The pathogenesis of IgA nephropathy and implications for treatment

New Insights into the Pathogenesis of IgA Nephropathy

The Oxford Classification of IgA Nephropathy: Rationale, Clinicopathological Correlations, and Classification.

Advances in the treatment of IgA nephropathy with biological agents

Childhood IgA nephropathy combined with Alport syndrome: a report of 2 cases and literature review

Title Page Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives